EGFR tyrosine kinase inhibitor "gefitinib (Iressa®)" for cancer therapy

Folia Pharmacologica Japonica

Volumn 122, Issue 6, 2003, Pages 491-497

  Yano, Seiichi ^a   Yamaguchi, Motonori ^a   Dong, Rui Ping ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Epidermal growth factor receptor; Gefitinib; Iressa ; Non small cell lung cancer; ZD1839

Indexed keywords

CYCLIN DEPENDENT KINASE 3; CYCLIN DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; KI 67 ANTIGEN; MESSENGER RNA; PROTEIN TYROSINE KINASE INHIBITOR;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; COLORECTAL CANCER; DOSE RESPONSE; DRUG POTENCY; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; METASTASIS; ONCOGENE C FOS; OVARY CANCER; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; FEMALE; GENES, FOS; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROTEIN-TYROSINE KINASES; QUINAZOLINES;

EID: 0346991841     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.122.491     Document Type: Review

References (24)

1. Downward J, Yarden Y, Mayes E, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature. 1984; 307:521-527.
2. Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor DNA sequence and aberrant expression of the amplified gene in A 431 epidermal carcinoma cells. Nature. 1984;309: 418-425.
3. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull. 1991;47:87-98.
4. Fontanini G, Vignati S, Bigini D, et al. Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer. 1995;31A:178-183.
5. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol/Hematol. 1995;19:183-232.
6. Gibson KH, Grundy W, Fodfrey AA, et al. Studies leading to the identification of ZD1839 (IressaTM): an orally active, selective EGF-receptor tyrosine kinase inhibitor targeted to the treatment of human tumour disease. Bioorg Med Chem Lett. 2001; 11:1911-1914.
7. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 ('Iressa'): an orally active inhibitor of epidermal growth factor signalling with potential for cancer therapy. Cancer Res. 2002;62:5749-5754.
8. Oliver BL, Sha'afi RI, Hajjar JJ. Transforming growth factor-α and epidermal growth factor activate mitogen-activated protein kinase and its substrates in intestinal epithelial cells. Proc Soc Exp Biol Med. 1995;210:162-170.
9. Wagstaff SC, Bowler WB, Gallagher JA, Hipskind RA. Extracellular ATP activates multiple signalling pathways and potentiates growth factor-induced c-fos gene expression in MCF-7 breast cancer cells. Carcinogenesis. 2000;21:2175-2181.
10. Chan KC, Knox WF, Gandhi A, Slamon DJ, Potten CS, Bundred NJ. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epidermal proliferation. Br J Surgery. 2001;88:412-418.
11. Gennaro ED, Barbarino M, Bruzzese F, Lorenzo SD, Caponigro F, Budillon A. Growth inhibition of tumor cells by epidermal growth factor tyrosine kinase inhibitor ZD1839 ('Iressa') is associated with upregulation of p27kip1 and p21cip1/waf1 cyclin-dependent kinase inhibitors. Proceedings of the 1999 AACR-NCI-EORTC International Conference. P. 25
12. Ciardiello F, Caputo R, Blanco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 2000;6:2053-2063.
13. Chan KC, Knox WF, Gee JM, et al. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res. 2002;62:122-128.
14. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 2002;20:110-124.
15. Ciardiello F, Caputo R, Blanco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res. 2001;7:1459-1465.
16. Kawaguchi M, Hosotani R, Kogire M, et al. Autoinduction and growth stimulatory effect of betacellulin in human pancreatic cancer cells. Int J Oncol. 2000;16:37-41.
17. Watson SA, Clifford TL, Steele RJ. Inhibitory effects of the gastrin receptor antagonist CR2093 on basal, gastrin-stimulated and growth factor-stimulated growth of the rat pancreatic cell line AR42J. Anticancer Drugs. 1994;5:591-597.
18. Takeshima E, Hamaguchi M, Watanabe T, et al. Aberrant elevation of tyrosine-specific phosphorylation in human gastric cancer cells. Jpn J Cancer Res. 1991;82:1428-1435.
19. Takekura N, Yasui W, Kyo E, et al. Effects of tyrosine kinase inhibitor, erbstatin, on cell growth and growth-factor / receptor gene expression in human gastric carcinoma cells. Int J Cancer. 1991;47:938-942.
20. Mueller H, Loop P, Liu R, Wosikowski K, Kueng W, Eppenberger U. Differential signal transduction of epidermal-growth-factor receptors in hormone-dependent and hormone-independent human breast cancer cells. Eur J Biochem. 1994;221:631-637.
21. Baselga J, Averbuch SD. ZD1839 ('Iressa') as an anticancer agent. Drugs. 2000;60 Suppl 1:33-40.
22. Yano S, Kondo K, Yamaguchi M, et al. Distribution and function of EGFR in normal human tissue, and the effect of EGFR Tyrosine Kinase Inhibition with ZD1839 ('Iressa'). Anticancer Res. (in press)
23. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signalling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001;61:7184-7188.
24. Wakeling AE. Epidermal growth factor receptor tyrosine kinase inhibitors. Curr Opin Pharmacol. 2002;2:382-387.